Telix Pharmaceuticals Conference Call Summary Company Overview - **Company**: Telix Pharmaceuticals (NasdaqGS:TLX) - **Industry**: Radiopharmaceuticals, focusing on oncology - **2025 Performance**: Achieved over $800 million in sales, primarily from the U.S. prostate cancer imaging franchise with two FDA-approved products [3][4] - **2026 Revenue Guidance**: Projected revenue between AUD 950 million and AUD 970 million, reflecting approximately 25% growth in the precision medicine business unit [5][6] Core Business Insights - **Focus Areas**: Urologic oncology and neuro-oncology [3] - **Growth Drivers**: - Continued growth in the PSMA (Prostate-Specific Membrane Antigen) imaging market, estimated at 5%-7% annually due to market education and increased urologist engagement [7] - Launch of a second prostate cancer product, Gozellix, which received pass-through status [8] - Ongoing Phase 3 BYPASS trial aimed at expanding the total addressable market (TAM) for prostate cancer imaging [9][10] Clinical Trials and Product Pipeline - **BYPASS Trial**: A significant Phase 3 trial that aims to improve biopsy accuracy using gallium PSMA PET scans, potentially reducing the need for invasive procedures [30][33] - **ProstACT Global Trial**: A Phase 3 trial for mCRPC (metastatic castration-resistant prostate cancer) that includes a randomized study design with various treatment cohorts [39][40] - **IPAX-BRIGHT Trial**: A Phase 3 trial for TLX101 in brain cancer, focusing on overall survival as the primary endpoint [68][71] - **TLX250 for Renal Cell Carcinoma**: Ongoing studies exploring combination therapies in a rapidly evolving treatment landscape [76][77] Market Opportunities and Challenges - **Prostate Cancer Imaging**: The BYPASS trial could lead to significant market expansion, with over 1 million biopsies performed annually in the U.S., many of which yield inconclusive results [30][31] - **Patient Compliance**: The potential to improve patient compliance and engagement through less invasive imaging techniques [38] - **Competitive Landscape**: The need to differentiate from other modalities, such as T-cell engagers, by emphasizing the short duration of treatment and integration into standard care [63][66] Future Directions - **Alpha Emitters**: Exploration of TLX592, an alpha emitter, with a focus on its potential advantages over beta emitters in targeting specific cancer types [54][58] - **Innovative Targets**: Plans to introduce novel targeting agents and expand the pipeline with a mix of validated and novel targets [92] - **Long-term Vision**: Aiming to establish a strong position in the radiopharmaceutical market by leveraging unique pharmacological approaches and addressing unmet medical needs [87][88] Conclusion - Telix Pharmaceuticals is positioned for significant growth in the oncology space, particularly in prostate cancer imaging and treatment, with a robust pipeline and strategic focus on innovative therapies. The company is actively addressing market challenges and exploring new opportunities to enhance patient outcomes and expand its market presence [3][4][5][6][7][8][9][10][30][31][39][40][68][71][76][77][87][88][92]

Summary of Telix Pharmaceuticals FY Conference Call Company Overview - **Company Name**: Telix Pharmaceuticals (NasdaqGS:TLX) - **Industry**: Targeted Radiopharmaceuticals - **Revenue**: Expected to be just under $1 billion for the year, primarily from precision medicine, specifically imaging [3][6] - **Global Presence**: Commercially active in 26 countries with a diverse R&D pipeline focused on therapeutic oncology [3][4] - **R&D Investment**: Approximately $300 million allocated for R&D and infrastructure development [3] Key Products Precision Medicine - **Illuccix**: - Flagship product launched in 2021, a PSMA-targeting agent. - Competes with Lantheus, which had a first-mover advantage. - Transitioned off transitional pass-through reimbursement in Q2 last year [9][10]. - **Gozellix**: - Lifecycle management product for Illuccix, with reimbursement secured. - Offers clinical advantages, including a longer shelf life and improved transport capabilities [10][11]. - Aims to service high-volume accounts and penetrate underserved areas [11][12]. Therapeutics - **TLX591**: - Antibody linked to lutetium-177, currently in a pivotal study for prostate cancer. - The study has transitioned to the randomized phase, with data expected soon [28][30]. - **Zircaix**: - Focused on renal cell carcinoma, with a BLA filed and expected to launch this year. - The company is harmonizing EU and US submissions to streamline the approval process [23][25][27]. Market Dynamics - **Prostate Imaging Market**: - Estimated growth of 5%-7% annually, driven by increasing awareness and clinical value of PSMA imaging [16]. - BiPASS trial aims to potentially double the market size by adding 800,000 scans [18][19]. - **PET Scanner Capacity**: - Increasing demand for PET scans due to growth in various disease areas. - New installations and advancements in scanner technology are expected to alleviate capacity issues [20][21]. Regulatory Challenges - **FDA Interactions**: - Experienced setbacks with two CRLs for glio and renal products, but ongoing collaboration with the FDA is noted as positive [24][26]. - Learning curve in submitting PET biologics, with expectations for approval still high [27]. Competitive Landscape - **Market Positioning**: - Aims to differentiate from competitors like Pluvicto by focusing on survival benefits and unique dosing regimens [47][49]. - Emphasizes the importance of OS (Overall Survival) as a key metric for success in the market [50][51]. Future Outlook - **Pipeline Development**: - Plans to expand therapeutic offerings with a focus on combination therapies, particularly in renal cancer [61]. - Anticipates significant data releases and product launches in 2026, with a strong emphasis on diagnostics and therapeutics [62]. Conclusion - Telix Pharmaceuticals is positioned as a significant player in the targeted radiopharmaceutical space, with a robust pipeline and strategic focus on both diagnostics and therapeutics. The company is navigating regulatory challenges while aiming for market differentiation through innovative product offerings and a strong emphasis on clinical outcomes.

Company Overview - Telix Pharmaceuticals focuses on radiopharmaceuticals for cancer diagnosis and treatment, emphasizing the importance of early detection in cancer care [1] - The company is developing cancer-targeting molecules that can be attached to radioactive isotopes for both detection and treatment of cancer [3] Market Growth - Cancer diagnostics is projected to grow at a compound annual rate of 8.33% from 2026 to 2035, reaching a market size of $378.4 billion [2] - Telix's revenue for 2025 was reported at $804 million, reflecting a 56% increase, with management forecasting 2026 revenue between $950 million and $970 million, a 19% increase at the midpoint [7] Product Development - Telix's lead products, Illuccix and Gozellix, are designed to identify prostate-specific antigen-positive cells using PET scans, with increasing regulatory approvals and recent U.S. launch of Gozellix [8] - The company has a robust R&D pipeline, including four late-stage and six early-stage candidates targeting various cancers, such as kidney cancer and glioblastoma [9] Clinical Trials - Telix is advancing two key drugs in phase 3 trials: TLX591 for prostate cancer and TLX250 for kidney cancer, both capable of using isotopes for detection and treatment [11] Competitive Advantage - The acquisition of RLS Pharmacies for $250 million has provided Telix with a distribution network, enhancing its competitive position in the radiopharmaceutical market [13] - This integrated ecosystem allows Telix to manage the distribution of its products more effectively compared to competitors reliant on external partners [13] Investment Potential - Analysts have a bullish outlook on Telix, with an average 12-month price target of $21.30, indicating significant upside potential from its current price of under $7 [14]

Core Viewpoint - The acceptance of the new drug application (NDA) for TLX591-CDx by the National Medical Products Administration marks a significant advancement for the company in the field of nuclear medicine for cancer diagnosis [1][2]. Group 1: Product Development and Market Potential - TLX591-CDx is a diagnostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), suitable for diagnosing both newly diagnosed and recurrent prostate cancer [1]. - The NDA application includes data from a clinical study conducted in China, which is a Phase III open-label study involving over 100 patients with biochemical recurrence of prostate cancer [1]. - The incidence of prostate cancer in China is on the rise, with projections indicating nearly 200,000 new cases by 2030 according to Frost & Sullivan data [1]. Group 2: Commercial Performance and Expansion - TLX591-CDx has been approved for commercialization in 24 countries, including Australia, the USA, and several European nations, demonstrating strong commercial performance with sales of approximately $517 million in 2024 and $461 million in the first three quarters of 2025, reflecting a year-on-year growth of over 25% [2]. - The acceptance of the NDA is a crucial step in the company's strategy to build an integrated diagnostic and therapeutic product portfolio for prostate cancer, with the complementary therapeutic product TLX591 already approved for international Phase III clinical studies in China [2]. Group 3: Strategic Positioning and Future Outlook - The company has established a comprehensive layout in the nuclear medicine sector, covering research and development, production, distribution, and sales [2]. - The ongoing "Go Global" strategy and the anticipated launch of TLX591-CDx and other innovative products are expected to enhance the company's core competitiveness in the nuclear medicine field [2].

Core Viewpoint - The acceptance of the new drug application (NDA) for TLX591-CDx by the National Medical Products Administration marks a significant advancement for the company in the nuclear medicine field, particularly for prostate cancer diagnosis, providing a leading-edge tool for early detection and treatment optimization [1][12]. Group 1: Market Potential and Clinical Data - Prostate cancer is increasingly prevalent in China, with an expected 200,000 new cases by 2030 and a market size projected to grow at a compound annual growth rate (CAGR) of approximately 21.8% to nearly 50.6 billion RMB [2][4]. - The overall positive predictive value (PPV) of TLX591-CDx in detecting tumors is reported at 94.8%, demonstrating its effectiveness compared to non-Chinese patient studies [9]. - Over 67.2% of patients had their treatment plans adjusted after undergoing PET imaging with TLX591-CDx, indicating its significant impact on clinical decision-making [9]. Group 2: Product Advantages and Technology - TLX591-CDx features a unique design with the PSMA-11 targeting agent, which binds specifically to PSMA expressed in prostate cancer, ensuring high diagnostic precision and safety [10][11]. - The product's characteristics include precise targeting, efficient imaging, and reliable safety, fulfilling clinical needs for early diagnosis and monitoring of prostate cancer [11]. Group 3: Strategic Development and Global Positioning - The acceptance of TLX591-CDx's NDA is a crucial step in the company's strategy to build an integrated diagnostic and therapeutic nuclear medicine product portfolio for prostate cancer [12]. - The company has established a comprehensive global layout in the nuclear medicine sector, with R&D and production bases in Boston and Chengdu, and a sales network covering over 50 countries [13]. - The company has a pipeline of 16 innovative products, including both diagnostic and therapeutic nuclear medicine options, aimed at various cancer types, enhancing its competitive edge [13]. Group 4: Future Outlook and Expansion - The successful international approval of the company's innovative small molecule RDC drug GPN01530 for clinical research signifies its strong clinical development capabilities and potential for future cancer imaging standards [16]. - The Chengdu production base, equipped with 14 high-standard GMP production lines, enables the company to meet diverse production needs and reduce reliance on imports, enhancing its operational efficiency [16]. - The ongoing "Go Global" strategy and the launch of innovative products like TLX591-CDx are expected to strengthen the company's competitive position in the global nuclear medicine market [17].

本次NDA申请包含了TLX591-CDx中国临床研究的数据，该研究于2025年12月公布了积极的初步结果， 该研究是一项单臂、开放标签的III期临床研究，在超过100例前列腺癌生化复发患者中使用TLX591- CDx并进行正电子发射断层成像/电脑断层扫描(PET/CT)或正电子发射断层成像/磁共振成像(PET/MRI) 检测，以评估产品的诊断有效性，同时评估产品在中国人群中的安全性和耐受性。根据临床顶线结果， TLX591-CDx检测肿瘤的总体阳性预测值(「PPV」)达94.8%(置信区间，CI：85.9%-98.2%)，证实了中国 患者使用TLX591-CDx诊断的临床经验与非中国患者的研究结果相当，即使在前列腺特异性抗原(PSA) 值极低的患者中，以及在不同的转移部位，其PPV也始终保持在较高水平。 格隆汇1月19日丨远大医药(00512.HK)公告，集团用于诊断前列腺癌的创新在研放射性核素偶联药物 (「RDC」)TLX591-CDx (Illuccix®, gallium Ga 68 PSMA-11)近日正式向中华人民共和国国家药品监督管 理局(「药监局」)递交了新药上市申请(「NDA」)并获得了受理， ...

Core Insights - The company has achieved significant breakthroughs in the field of nuclear medicine, particularly with the successful completion of the Phase I clinical trial of TLX250-CDx for diagnosing clear cell renal cell carcinoma (ccRCC) in China, which has been published in a leading international journal [1][6] - TLX250-CDx is expected to provide a non-invasive and accurate diagnostic option for millions of suspected ccRCC patients in China, enhancing the diagnostic landscape [1][6] Group 1: Clinical Research and Results - The ZIRDOSE-CP clinical study is a single-arm, open-label, prospective Phase I trial assessing the safety, tolerability, and pharmacokinetics of TLX250-CDx in 10 Chinese patients with uncertain renal masses or suspected recurrence of ccRCC [2] - The study demonstrated good safety and tolerability of TLX250-CDx in Chinese patients, with organ and tumor dosimetry similar to previous reports in other populations, supporting its clinical value [6][10] Group 2: Market Potential and Growth - The ccRCC market is expanding, with the number of patients in China increasing from 66,000 in 2015 to 81,000 in 2023, reflecting a compound annual growth rate (CAGR) of 2.0%, and projected to reach 93,000 by 2030 [2] - The global renal cancer diagnostic market is expected to grow from USD 5.37 billion in 2024 to USD 8.36 billion by 2035, with a CAGR of 4.11%, indicating a strong demand for more precise diagnostic methods [5] Group 3: Company Capabilities and Innovations - The company has established a comprehensive nuclear medicine industry chain, covering research, production, distribution, and sales, with over 900 employees globally [7][14] - The company has a robust pipeline with 16 innovative products in the registration phase, including five key radioactive isotopes, and aims to provide integrated treatment options for various cancers [7][10] - The company’s production facility in Chengdu is the world's first closed-loop platform for nuclear medicine, ensuring 100% self-production and addressing import dependency issues [12][14]

Core Insights - The company, YuanDa Pharmaceutical, has achieved significant breakthroughs in the field of nuclear medicine for cancer diagnosis, particularly with the successful completion of the Phase I clinical trial of TLX250-CDx for diagnosing clear cell renal cell carcinoma (ccRCC) in China [1][6]. Group 1: Clinical Research and Results - TLX250-CDx has demonstrated good safety and tolerability in Chinese patients, with organ and tumor dosimetry similar to previous reports in other populations, supporting its safety and efficacy for future registration and market launch in China [1][6]. - The ZIRDOSE-CP clinical study, a single-arm, open-label, prospective Phase I trial, evaluated the safety, tolerability, and pharmacokinetics of TLX250-CDx in 10 Chinese patients with uncertain renal masses or suspected recurrence of ccRCC [2][5]. - The sensitivity and specificity of TLX250-CDx for detecting ccRCC were reported at 85.5% and 87%, respectively, indicating its potential as a new clinical diagnostic standard [5][6]. Group 2: Market Potential and Growth - The ccRCC patient population is growing, with the incidence in China increasing from 66,000 in 2015 to 81,000 in 2023, reflecting a compound annual growth rate (CAGR) of 2.0%, and projected to reach 93,000 by 2030 [2]. - The global renal cancer diagnostic market is expected to grow from USD 5.37 billion in 2024 to USD 8.36 billion by 2035, with a CAGR of 4.11%, highlighting the demand for more precise and efficient diagnostic methods [5]. Group 3: Company Capabilities and Innovations - YuanDa Pharmaceutical has established a comprehensive nuclear medicine industry chain, covering research, production, distribution, and sales, with over 900 employees globally [7][14]. - The company has a strong pipeline of 16 innovative products in the registration phase, including five key radioactive isotopes, and aims to provide integrated treatment options for various cancers [7][10]. - The company’s production facility in Chengdu is the world's first closed-loop platform for nuclear medicine, ensuring 100% self-sufficiency in production and addressing import dependency issues [12][14].

Core Viewpoint - The recent advancements in the nuclear medicine pipeline of the company signify a major breakthrough, particularly with the FDA approval of the innovative radioactive drug conjugate (RDC) GPN01530 and the positive results from the Phase III clinical trial of TLX591-CDx for prostate cancer diagnosis, indicating imminent commercialization prospects [1][2]. Group 1: Product Development and Clinical Results - TLX591-CDx is a globally innovative diagnostic radioactive drug targeting prostate-specific membrane antigen (PSMA), showing a high positive predictive value (PPV) of 94.8% for overall tumor detection and 100.0% for recurrence in the prostate bed and non-bone metastatic tumors [2][3]. - The successful Phase III clinical trial results for TLX591-CDx provide robust evidence for its high accuracy and clinical utility in diagnosing prostate cancer, supporting its upcoming new drug application in China [3][4]. Group 2: Market Potential and Strategic Positioning - TLX591-CDx has demonstrated strong sales performance globally, with projected sales of approximately $517 million in 2024 and $461 million in the first three quarters of 2025, reflecting a growth rate exceeding 25% [3]. - The success of TLX591-CDx in China marks a significant step in the company's strategy to build an integrated diagnostic and therapeutic product portfolio for prostate cancer, which is expected to enhance treatment standards and improve patient quality of life [4].

Core Viewpoint - The company has achieved positive topline results in the Phase III clinical trial of its innovative radiopharmaceutical TLX591-CDx for prostate cancer diagnosis, meeting the primary clinical endpoint [1] Group 1: Product Development - TLX591-CDx is a globally innovative diagnostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), suitable for both initial diagnosis and recurrent prostate cancer [1] - The company has secured exclusive rights for multiple innovative RDC products, including TLX591-CDx, in Greater China through a strategic cooperation agreement with Telix [1] - TLX591-CDx has been approved for sale in several countries, including the US, Australia, Canada, Brazil, and the UK, with projected sales of approximately $517 million in 2024 and $461 million in the first three quarters of 2025, reflecting a year-on-year growth of over 25% [1] Group 2: Research and Development - The company has initiated an international multicenter Phase III clinical study for another innovative RDC product, TLX591, in China [2] - The company has established a comprehensive layout in the nuclear medicine sector, covering research, production, distribution, and sales, with R&D bases in Boston and Chengdu [2] - The product pipeline includes 16 innovative products in the research registration stage, utilizing five types of radioactive isotopes and covering seven cancer types, including liver cancer and brain cancer [2] Group 3: Industry Positioning - The company has six innovative RDC products approved for registration clinical research, with four currently in Phase III clinical trials, indicating a harvest period for innovative nuclear medicine products [2] - The nuclear medicine R&D and production base in Chengdu received a Class A Radiation Safety License in May 2025 and commenced operations in June 2023, meeting the demand for various therapeutic and diagnostic nuclear medicines [2]